CCND1 and non-Hodgkin lymphoma: The impact of these findings may extend beyond MCL, as cyclin D1 overexpression is seen in about 10%–20% of NHL and other hematologic malignancies (33); in solid tumors, including 50% of breast and colon cancers (60, 61); and in 80% of pancreatic cancer (62).